Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial

Overview of attention for article published in Experimental Hematology & Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#9 of 354)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter: 37 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 37 X posts from 37 X users, with an upper bound of 28,813 followers.

Small number of patients, but still promising results for Dauno/Ara-C (2+6) + Ven. Would be nice to see a head to head comparison between FLAG-ida +Ven and this regimen. #AML

27 May 2023

Reply Repost Favourite

RT @smbenlazar: Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute…

27 May 2023

Reply Repost Favourite

RT @smbenlazar: Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute…

27 May 2023

Reply Repost Favourite

RT @smbenlazar: Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute…

22 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 33 additional X posts.